Biotech & MedTech
-
Hemostemix Plans to Revolutionize Stem Cell Therapy with Scalable Production and New Sales Goals
Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0) has developed an effective “stem cell therapy” for…
-
Steve Saviuk, CEO of Valeo Pharma, Discusses Promising Results of COVID-19 Drug Sabizabulin and Revenue Growth in 2023
In this InvestorIntel interview, Tracy Weslosky talks to Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO, and…
-
Zentek’s ZenARMOR is potentially a major breakthrough in the US$23.8B+ Global Anti-Corrosion Coatings Market
The anti-corrosion coatings market may not sound very glamorous, but it is a multi-billion dollar business. According to…
-
Valeo Pharma’s CEO Steve Saviuk Talks about Record FQ4 & F2022 Revenue Up 274% & 105%, Respectively
In this InvestorIntel interview, Tracy Weslosky talks to Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO,…
-
Greg Fenton on ZenARMOR, Zentek’s novel corrosion protection technology
In this InvestorIntel interview, Tracy Weslosky talks to Zentek Ltd.‘s (NASDAQ: ZTEK | TSXV: ZEN) CEO and Director Greg…
-
Greg Fenton on the impact of Zentek’s HVAC Phase 2 Testing results on Air Filtration
In this InvestorIntel interview, Tracy Weslosky talks to Zentek Ltd.‘s (NASDAQ: ZTEK | TSXV: ZEN) CEO and Director…
-
Record revenues in 2022 of $27.7 million, Valeo Pharma investment in commercial infrastructure starts to pay off
What a difference a year makes. Last year at this time we were heading into wave something or…
-
David Elsley of Cardiol Therapeutics talks about their global Phase II clinical trials for the treatment of heart diseases
In this InvestorIntel interview, Chris Thompson talks to Cardiol Therapeutics Inc.’s (NASDAQ: CRDL | TSX: CRDL) CEO, President and…
-
David Regan of Sona Nanotech provides an update on its agreement with Siva Therapeutics to develop cancer treating therapies
In this InvestorIntel interview, Sona Nanotech Inc.’s (CSE: SONA | OTCQB: SNANF) CEO David Regan provides Tracy Weslosky with…
-
Thomas Smeenk provides an update on Hemostemix’s ACP-01 stem cell treatment for heart disease
Peter Clausi interviews Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, President and CEO Thomas Smeenk about an…